Clinical trial Recruiting at 1 site Phase 4 Interventional Ages Any age to 28 Days

Dopamine versus norepinephrine for low blood pressure in newborns with pulmonary hypertension

Official title: Dopamine vs. Norepinephrine in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure and Systemic Hypotension Due to Pulmonary Hypertension: A Pilot Trial

Run by University of California, Davis · NCT07322133 · Data updated 2026-11-12

This pilot test compares norepinephrine and dopamine as the first medicine to raise blood pressure in term and late‑preterm newborns with pulmonary hypertension and hypoxemic respiratory failure.

More Acute Hypoxemic Respiratory Failure trials

Quick facts

PhasePhase 4
Study typeInterventional
AgesAny age to 28 Days
SexAll
Enrollment30 (estimated)
SponsorUniversity of California, Davis
Academic / other
Locations1 site (Sacramento, California)
StatusRecruiting
StartedOctober 30, 2026
Main results expectedJune 30, 2027
Study endsJune 30, 2027
Registry record updatedAugust 18, 2026
Trial IDNCT07322133 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Term and late‑preterm infants (postmenstrual age >34 6/7 weeks and postnatal age ≤28 days) on respiratory support with echocardiographic pulmonary hypertension and systemic hypotension despite a 10–20 mL/kg fluid bolus are the intended participants.

Probably not a fit

Extremely preterm infants (<32 weeks), those with severe refractory hypoxic respiratory failure (OI >35 or SpO2 <75% on 100% FiO2), lethal anomalies, or complex congenital heart disease are excluded and would not be expected to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, cluster-randomized pilot trial at UC Davis enrolling term and late‑preterm neonates with echocardiographic pulmonary hypertension, hypoxemic respiratory failure, and systemic hypotension that persists after a fluid bolus. Eligible infants on respiratory support and meeting blood pressure and oxygenation criteria are randomized to receive either dopamine or norepinephrine as first-line vasoactive therapy. The study measures short-term hemodynamic and oxygenation responses after initiation of the assigned vasopressor. The goal is to compare effects on systemic blood pressure and pulmonary vascular tone to inform choice of initial vasopressor in PPHN.

Why it matters

Potential benefit: If successful, the trial could identify a vasopressor strategy that raises systemic pressure without worsening pulmonary vascular resistance, improving oxygenation and clinical stability for affected newborns.

How similar studies have gone: There are animal and observational data suggesting dopamine may raise pulmonary vascular resistance and norepinephrine may spare the pulmonary circulation, but there are no prior prospective randomized trials directly comparing these drugs in neonates with PPHN.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Postmenstrual age \> 34 6/7 weeks and Postnatal age ≤ 28 days
2. On respiratory support (Invasive mechanical ventilation, NIPPV, CPAP, HFNC ≥ 2 LPM) and FiO2 ≥ 0.3
3. Echocardiographic evidence of pulmonary hypertension
4. Mean arterial pressure below the threshold for gestational age despite a 10-20 mL/kg fluid bolus

Permissible Comorbidities: CDH, trisomy 21, HIE on hypothermia, PDA, PFO/ASD, VSD \< 2 mm

Exclusion Criteria:

1. Gestational age \< 32 weeks
2. Severe hypoxic respiratory failure (OI \> 35 or SpO2 \< 75% on 100% FiO2 for \> 60 minutes)
3. Lethal anomalies (e.g., trisomy 13 or 18)
4. Complex congenital heart disease beyond specified criteria

Where it's running

  • UC Davis Children's Hospital
    Sacramento, California, United States
    Recruiting

Study contacts

  • Principal investigator: Deepika Sankaran, MD — UC Davis Health
  • Study coordinator: Solomon P Tatagiri, MBBS
  • Email: solomontp@gmail.com
  • Phone: 916-734-8672

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.